Announced
Completed
Synopsis
Swisscanto and imec.xpand led a CHF12.4m Series A round in Nagi Bioscience, a Swiss life sciences company developing next-generation laboratory equipment to unlock the alternatives to animal testing, with participation from Excellis, Verve Ventures, and Zürcher Kantonalbank. “The enthusiastic support from our new investors reflects our belief in Nagi’s potential to disrupt the drug discovery and toxicology testing markets. We are deeply grateful for their trust in our vision. This substantial investment is a testimony of the hard work, dedication, and passion of our incredible team and will be instrumental now in scaling-up the commercial organization and operations, while expanding R&D activities to strengthen Nagi’s portfolio of innovative products,” Matteo Cornaglia, Nagi Bioscience, CEO and Co-Founder.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.